by using Marisa Taylor and Dan Levine
Sept 10 (Reuters) - appropriate U.S. health officers believe that Pfizer Inc's COVID-19 vaccine could be authorized for little ones aged 5-eleven years old through the conclusion of October, two sources familiar with the circumstance pointed out on Friday.
The timeline is according to the expectation that Pfizer, which developed the shot with Germany's BioNTech, can have adequate statistics from scientific trials to seek emergency use authorization (EUA) for that age group from the U.S. meals and Drug Administration against the conclusion of this month, the sources observed.
They count on the FDA might make a call on even if the shot is secure and helpful in younger infants within three weeks of the EUA submission. (Reporting via Marisa Taylor in Washington and Dan Levine in San Francisco; modifying by using Michele Gershberg, Caroline Humer)
0 Comments